Doctors and scientists who work at research institutions invent many of the diagnostic tests, treatments, and therapies used to care for patients. In some cases, MSK has rights to our inventions, called intellectual property rights. MSK licenses the rights to our inventions to companies that can develop or improve what we created.
These arrangements ensure our treatments have the ability to reach as many people as possible. It also advances public health by making new treatments available to many more patients.
Through these licensing arrangements, MSK has standard rights to earn payments from the companies that licensed our inventions. This could include royalty payments, milestone payments, equity interests, research funding, and other financial arrangements. We call all these payments “financial interests.”
The list below has information about drugs and products that were invented at MSK that MSK has a current financial interest in. They are approved by the US Food and Drug Administration (FDA).
This information is current as of July 27, 2021.
|Commercial Name||Product Type||Company||Approved by FDA|
|Breyanzi (lisocabtagene maraleucel)||Drug||Bristol-Myers Squibb||2021|
|Danyelza (naxitamab-gqgk)||Drug||Y-mAbs Therapeutics||2020|
|Erleada (apalutamide)||Drug||Janssen Biotech||2018|
|Folotyn (pralatrexate)||Drug||Allos Therapeutics||2009|
|Abecma (ide-cel)||Drug||Bristol-Myers Squibb||2021|
|FullFocus Viewer||Device (pathology slide viewer)||Paige.AI||2020|
MSK makes decisions based on its mission and duty to patients and in alignment with the institution’s core values and code of conduct.
If you have questions regarding these products as they relate to MSK’s interests, please contact MSK’s Conflict of Interest Office: [email protected]